OrganoTherapeutics has the mission to accelerate the development of therapeutics against neurodegeneration.

The current focus of OrganoTherapeutics is on Parkinson’s disease. Our team is convinced that therapeutics targeting complex human disease like Parkinson’s, need to be developed with complex human patient specific models.

Our team has developed PD patient specific cell culture models, organoids and assembloids, that replicate the Parkinson’s pathology and - to an extent - that cannot be found in any other cell culture or animal model.

The organoid and assembloid models are IP protected and have been used in the past 6 years in joint projects with academic and industry partners from Europe, USA and Japan.